Back to Search
Start Over
High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer
- Source :
- Bone Marrow Transplantation. 19:1183-1189
- Publication Year :
- 1997
- Publisher :
- Springer Science and Business Media LLC, 1997.
-
Abstract
- The purpose of this study was to determine the outcome of patients with metastatic breast cancer treated with high-dose busulfan (Bu), melphalan (Mel) and thiotepa (TT) followed by peripheral blood stem cell (PBSC) infusion. Fifty-one patients with chemotherapy refractory (n = 32) or responsive (n = 19) metastatic breast cancer received Bu (12 mg/kg), Mel (100 mg/m2) and TT (500 mg/m2) followed by PBSC collected after chemotherapy and growth factor (n = 43) or growth factor alone (n = 8). The 100 day treatment-related mortality was 8% including one death from cytomegalovirus pneumonia, one from aspiration pneumonia and two from regimen-related toxicity (RRT). Seven of 28 refractory (25%) and 5/7 (71%) responsive patients with evaluable disease achieved a complete response of all measurable disease or all soft tissue disease with at least improvement in bone lesions (PR*). Fifteen of 51 patients (29%) are alive and progression-free a median of 423 days (range 353-934) after treatment, 5/32 (16%) with refractory disease and 10/19 (53%) with responsive disease. The probabilities of progression-free survival (PFS) at 1.5 years for the patients with refractory (n = 32) and responsive (n = 19) disease were 0.24 and 0.53, respectively. These preliminary data suggest that high-dose Bu/Mel/TT has significant activity in patients with advanced breast cancer and may be superior to some previously published regimens.
- Subjects :
- Adult
Melphalan
medicine.medical_specialty
medicine.medical_treatment
Drug Resistance
Breast Neoplasms
ThioTEPA
Transplantation, Autologous
Gastroenterology
Breast cancer
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Busulfan
Survival rate
Aged
Transplantation
Chemotherapy
business.industry
Graft Survival
Hematopoietic Stem Cell Transplantation
Cancer
Hematology
Middle Aged
Prognosis
medicine.disease
Combined Modality Therapy
Metastatic breast cancer
Surgery
Survival Rate
Female
business
Thiotepa
medicine.drug
Subjects
Details
- ISSN :
- 14765365 and 02683369
- Volume :
- 19
- Database :
- OpenAIRE
- Journal :
- Bone Marrow Transplantation
- Accession number :
- edsair.doi.dedup.....728190d47a695cdb63c3b663089dbcfc